NCT01249131View on ClinicalTrials.gov

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

December 1, 2010

Primary Completion Date

January 10, 2011

Study Completion Date

January 10, 2011

Conditions

Healthy Volunteers

Interventions

DRUG

Cobimetinib

Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY